cadila healthcare (Emkay) Results in-line; Maintain Accumulate

Launch of Texotere, Domestic formulation and US business aided 43% revenue growth; Growth will continue going forward due to multiple growth drivers
Date Rating Target Price Recommendation Price Broker house
6 May 2011 accumulate 920 850 Emkay Report

No comments:

Post a Comment